



Rituxan[®] (rituximab) – New orphan indication

- On June 7, 2018, [Genentech announced](#) the FDA approval of [Rituxan \(rituximab\)](#) intravenous (IV) infusion, for the treatment of adult patients with moderate to severe pemphigus vulgaris (PV).
- Rituxan is also approved to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, granulomatosis with polyangiitis (Wegener's granulomatosis), and microscopic polyangiitis.
- PV is an autoimmune, potentially life-threatening, blistering disease affecting the skin and mucous membranes. It affects 30,000 to 40,000 people in the U.S.
- The efficacy of Rituxan in PV was demonstrated in an open-label study enrolling 90 newly-diagnosed adults with pemphigus. Patients received rituximab and prednisone or prednisone alone. The primary endpoint was complete remission (complete epithelialization and absence of new and/or established lesions) at month 24.
 - For PV, 90% of Rituxan and prednisone-treated patients vs. 28% of prednisone-treated patients met the primary endpoint.
- Rituxan carries a boxed warning for fatal infusion reactions, severe mucocutaneous reactions, hepatitis B virus reactivation and progressive multifocal leukoencephalopathy.
- The most common adverse reactions ($\geq 15\%$) with Rituxan use in PV were infusion reactions and depression. Other important adverse reactions are infections.
- The recommended dosage of Rituxan for PV is as follows: administer Rituxan as two-1,000 mg IV infusions separated by 2 weeks in combination with a tapering course of glucocorticoids.
 - For maintenance treatment, administer Rituxan as a 500 mg IV infusion at month 12 and every 6 months thereafter or based on clinical evaluation.
 - For treatment of relapse, administer Rituxan as a 1,000 mg IV infusion on relapse, and consider resuming or increasing the glucocorticoid dose based on clinical evaluation.
 - Consult the Rituxan drug label for further information and for dosing recommendations for all other indications.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.